Key clinical point: Higher body mass index (BMI) and more disturbed sleep were identified as correlates of more severe fatigue, which worsen the quality of life (QoL) in patients with chronic-phase chronic myeloid leukemia (CML-CP) on tyrosine kinase inhibitor (TKI) therapy with self-reported fatigue of at least moderate severity.
Major finding: Higher BMI ( P = .01) and more sleep disturbance ( P less than .01) were significant correlates of more severe fatigue. Worse fatigue was associated with reduced health-related QoL ( P less than .01).
Study details: This study assessed preintervention data from the CBT-TTF trial including 44 adult patients with CML-CP treated with TKIs who self-reported at least moderate fatigue.
Disclosures: This study was funded by the National Cancer Institute. HSL Jim reported consulting for RedHill BioPharma, Janssen Scientific Affairs, and Merck. Other authors declared no conflicts of interest.
Source: Oswald LB et al. Support Care Cancer. 2021 Jul 7. doi: 10.1007/s00520-021-06408-1 .